PDS Biotechnology (PDSB) Other Working Capital Changes (2020 - 2023)
PDS Biotechnology's (PDSB) quarterly Other Working Capital Changes came in at -$60333.0 in Q3 2023, up 32.29% YoY from -$45607.4 in Q3 2022, and up 32.99% on a QoQ basis from -$90034.0 in Q2 2023.
PDS Biotechnology (PDSB) Other Working Capital Changes (2020 - 2023) Analysis & Trends
PDS Biotechnology (PDSB) has 4 years of Other Working Capital Changes data on file, last reported at -$60333.0 in Q3 2023.
- Quarterly Other Working Capital Changes rose 32.29% year-over-year to -$60333.0 in Q3 2023, while the trailing twelve-month figure through Jun 2024 was -$60333.0 (up 83.12% YoY) and the FY2023 annual result came in at -$239469.0, up 18.82% from the prior year.
- Other Working Capital Changes grew to -$60333.0 in Q3 2023, from -$90034.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $3.4 million in Q1 2025 to a low of -$4.7 million in Q4 2025.
- A 5-year average of $102037.6 and a median of -$16783.0 in 2021 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2021 — Other Working Capital Changes tumbled 168.76% — and 2023, when it jumped 32.29%.
- Tracing PDSB's Other Working Capital Changes over 4 years: stood at -$35536.0 in 2020, then decreased by 21.1% to -$43035.0 in 2021, then sank by 107.05% to -$89103.0 in 2022, then jumped by 32.29% to -$60333.0 in 2023.
- The last three Other Working Capital Changes figures came in at -$60333.0 (Q3 2023), -$90034.0 (Q2 2023), and -$89102.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | PDS Biotechnology | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -60,333.00 |
| Sep 30, 2023 | -60,333.00 |
| Sep 30, 2023 | -60,333.00 |
| Jun 30, 2023 | -90,034.00 |
| Jun 30, 2023 | -90,034.00 |
| Jun 30, 2023 | -90,034.00 |
| Mar 31, 2023 | -89,102.00 |
| Mar 31, 2023 | -89,102.00 |
| Mar 31, 2023 | -89,102.00 |
| Dec 31, 2022 | -89,103.00 |
| Dec 31, 2022 | -89,103.00 |
| Dec 31, 2022 | -89,103.00 |
| Sep 30, 2022 | -89,102.00 |
| Sep 30, 2022 | -89,102.00 |
| Sep 30, 2022 | -89,102.00 |
| Jun 30, 2022 | -73,747.00 |
| Jun 30, 2022 | -73,747.00 |
| Jun 30, 2022 | -73,747.00 |
| Mar 31, 2022 | -43,036.00 |
| Mar 31, 2022 | -43,036.00 |